Allergan's BOTOX Wins FDA Nod For Neurologic Condition-Associated Pediatric Detrusor Overactivity

by Vandana Singh, Benzinga Editor

February 10, 2021 11:05 AM | 1 min read | Make a Comment

The FDA has approved Allergan and AbbVie Inc's (NYSE: ABBV) BOTOX (onabotulinumtoxinA). It is used to treat detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
Neurogenic detrusor overactivity occurs when the spinal cord and bladder are not able to communicate effectively. As a result, the bladder muscle involuntarily contracts, increasing the bladder's pressure and reducing the bladder capacity, which can cause the individual to leak urine frequently and unexpectedly.
Price Action: ABBV share are down 0.68% at $104.68 on the last check Wednesday.

Posted In: Biotech News Health Care FDA General BOTOX

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.